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Background: Prolonged or excessive blood loss is a common complication after cardiac surgery. Blood remnants
and clots, remaining in the pericardial space in spite of chest tube drainage, induce high ﬁbrinolytic activity that
may contribute to bleeding complications. Continuous postoperative pericardial ﬂushing (CPPF) with an irriga-
tion solution may reduce blood loss by preventing the accumulation of clots. In this pilot study, the safety and
feasibility of CPPF were evaluated and the effect on blood loss and other related complications was investigated.
Methods: Between November 2011 and April 2012 twenty-one adult patients undergoing surgery for congenital
heart disease (CHD) received CPPF from sternal closure up to 12 h postoperative. With an inﬂow Redivac drain
that was inserted through one of the chest tube incision holes, an irrigation solution (NaCl 0.9% at 38 °C) was
delivered to the pericardial cavity using a volume controlled ﬂushing system. Safety aspects, feasibility issues
and complications were registered. The mean actual blood loss in the CPPF group was compared to the mean
of a retrospective group (n = 126).
Results: CPPF was successfully completed in 20 (95.2%) patients, and no method related complications were
observed. Feasibility was good in this experimental setting. Patients receiving CPPF showed a 30% (P = 0.038)
decrease in mean actual blood loss 12 h postoperatively.
Conclusions: CPPF after cardiac surgery was found to be safe and feasible in this experimental setting. The
clinically relevant effect on blood loss needs to be conﬁrmed in a randomized clinical trial.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prolonged or excessive bleeding is one of themost common compli-
cations after cardiac surgery. Postoperative bleeding requiring transfu-
sions and surgical re-exploration remains an important complication
because it is associated with short- and long-term postoperative
mortality, morbidity, prolonged hospitalization, and higher societal
healthcare costs (Murphy et al., 2007).
The mechanisms involved in perioperative bleeding are complex
and involve disturbances in various physiologic systems including
primary hemostasis, coagulation, and ﬁbrinolysis. This may be caused
by several surgical factors including cardiopulmonary bypass (CPB)
and operative trauma. Together with primary ﬁbrinolysis, plateletcic Surgery, Academic Medical
9, 1105 AZ Amsterdam, The
ergen).
. This is an open access article underdysfunction, and hemodilution these mechanisms contribute to dys-
function of the coagulation, ﬁbrinolytic, and inﬂammatory systems
with postoperative coagulopathy and bleeding as a result (Paparella
et al., 2004; Despotis et al., 2001). Consequently, the normal or generally
accepted amount of blood loss after cardiac surgery is higher than most
other surgical specialties and varies between 300–1500 ml during the
ﬁrst 12 h.
The standard operating procedure is to insert chest tubes in order to
evacuate this blood from the pericardial cavity postoperatively. Howev-
er, if blood loss or clot formation is excessive the chest tubes often fail
due to partial or complete blockage. The resulting stasis of blood and
clots in the pericardial cavity leads to high ﬁbrinolytic activity and con-
sequently, maintenance of blood loss (Despotis et al., 2001; Philippou
et al., 2000; Illig et al., 1997; Yavari and Becker, 2009; Vallely et al.,
2009). This is also supported by the ﬁnding that during re-exploration
for postoperative bleeding, removal of accumulated blood and clots by
solely irrigating the pericardial space with a warm saline solution is
enough to stop the bleeding instantly in a signiﬁcant number of cases
(Pelletier et al., 1998). Following on from this, a method of preventingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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thetically stop postoperative bleeding at an earlier stage and reduce
bleeding complications. Continuous postoperative pericardial ﬂushing
(CPPF) was developed for this purpose.
CPPF works by continuously ﬂushing the pericardial cavity with a
warm saline irrigation solution starting towards the end of surgery
just before sternal closure. Continuousﬂushingwill result in a lower vis-
cosity mixture that will prevent chest tube blockages and promote the
evacuation of blood and clots from the pericardial cavity. This pilot
study evaluates the safety and feasibility of CPPF. In addition, its effects
on blood loss and other related complications are investigated and
discussed. To our knowledge, the continuous pericardial ﬂushing
method post-cardiac surgery has not been used or described before.
Abbreviations
ACT activated clotting time
AMC Academic Medical Center, Amsterdam, The Netherlands
CHD congenital heart disease
CPB cardiopulmonary bypass
CPPF continuous postoperative pericardial ﬂushing
CRP C-reactive protein
FFP fresh frozen plasma
ICU intensive care unit
IU international unit
MCTD mediastinal chest tube drainage
METC medical ethics committee
PRBC packed red blood cell
TTE transthoracic echocardiogram
2. Methods
2.1. Study Design
In this pilot study, a prospective cohort of patients who underwent
surgery and CPPF between November 2011 and April 2012 (n = 21,
over a 6-month inclusion period) was compared to a retrospective
group of patients who underwent surgery and no CPPF (non-CPPF
group) between January 2010 and December 2011 (n = 126). The
study protocol was approved by the internal review board of the Aca-
demic Medical Center (AMC) Amsterdam, protocol number METC
2011_270. All adult patients undergoing surgical correction for congen-
ital heart disease (CHD) were eligible to participate in this prospective
cohort study. Exclusion criteria were emergency surgery, a history of
bleeding diathesis or coagulopathy, participation in any study involving
an investigational drug or device, and the inability to understand the
study information or give informed consent. Informed consent was ob-
tained one day preoperatively from all patients in the CPPF group and
data were gathered prospectively. Data from the non-CPPF group
were obtained retrospectively by analyzing consecutive patient records
before the use of CPPF for a period of 24months. All patients underwent
cardiac surgery at the AMC, which is a quaternary care university
hospital. A single surgeon performed surgery on all included patients
in the CPPF group and almost all of the patients in the non-CPPF.
2.2. Continuous Postoperative Pericardial Flushing
Themethod of inserting chest tubes in the CPPF groupwas the same
as routinely used in the non-CPPF group; one chest tube (Ch30 Redivac
drain, Medica Europe, Oss, The Netherlands) in the pericardial
space, one chest tube (Ch30 Redivac drain, Medica Europe, Oss, The
Netherlands) in the anterior mediastinum and in case of opened pleural
spaces they were each drained separately (Ch30 Redivac drain, Medica
Europe, Oss, The Netherlands). In the CPPF group an extra infusion tube
(Ch10 Redivac drain, Dispo Medical, Hattemerbroek, The Netherlands)
was inserted through the incision hole of one of the standard chest
tube incisions and positioned in the pericardial space. This extrainfusion tubewas directly connected to the CPPF system that comprises
a bag of irrigation solution (NaCl 0,9%) connected to infusion line that
runs through a volumetric pump (Infusomat® Space by B. Braun,
Melsungen, Germany) and through a ﬂuid heating device (Enﬂow®
ﬂuid warmer by GE Healthcare, Hoevelaken, The Netherlands). CPPF
was started at sternal closure and continued for 12 h postoperatively.
The irrigation solution NaCl 0.9%, was delivered to the pericardial cavity
at a ﬂow rate of 500 ml/h for the ﬁrst two postoperative hours. It was
then set to volume controlled for the next ten hours so that the volume
corresponded with the patients' actual blood loss at a 1:1 ratio, with a
minimum ﬂow rate of 100 ml/h. The irrigation solution was delivered
to the patient at a constant temperature of 38 °C to avoid changes in pa-
tient core temperature. Irrigation solution volume and totalmediastinal
chest tube drainage (MCTD) volume were monitored every 15 min for
the ﬁrst two postoperative hours and thereafter hourly until chest
tube removal. Actual blood loss was calculated at the same time inter-
vals by subtracting irrigation solution volume from the total MCTD vol-
ume. In this way, a secondary manually written record was kept to
monitor actual blood loss and trace ﬂuid accumulation. If MCTD volume
was N200 ml less than the infused irrigation solution volume, the CPPF
system was stopped to prevent accumulation of ﬂuid in the pericardial
and/or pleural spaces. One and the same research assistant facilitated
both preparation of the CPPF system and the safeguarding and control
of the system during the CPPF window.
2.3. Operative Procedures and Cardiopulmonary Bypass Management
Routine anesthetic procedures were employed making circum-
stances standardized and equal for both groups. All patients underwent
full median sternotomy; CPB (Stöckert S5, Sorin Group, Italy) was
instituted in all patients using mild hypothermia (30–32 °C). Before
initiation of CPB, all patients received a standard heparin dosage of
150 IU/kg bodyweight with an additional optional bolus of 50 IU/kg
before cannulation. Anticoagulation was monitored by serial measure-
ments of the activated clotting time (ACT), which was kept above
450 s at all times during CPB. The heparin was reversed by administra-
tion of 1 ml protamine for each 1000 IU heparin and ACT return to
baseline served as conﬁrmation.
2.4. Transfusion Policies
A standardized transfusion protocol was followed in all patients. In-
traoperative blood management included reinfusion of residual blood
from the cardiotomy reservoir and packed red blood cell (PRBC) trans-
fusion during CPB were given at hemoglobin levels b4.0 mmol/l. Post-
operative blood management on the ICU included PRBC transfusions
for hemoglobin level b5.0 mmol/l; platelet concentrate for platelet
count b50 × 109/l or b100 × 109/l if blood loss exceeded 150 ml/h
and fresh frozen plasma (FFP) was transfused if the activated partial
thromboplastin time and prothrombin time were prolonged N150%
during active bleeding.
2.5. Primary Endpoints
The primary endpoints of this pilot studywere to evaluate the safety
and feasibility of CPPF procedure and its effect on actual blood loss.
Safety endpoints during hospitalization were deﬁned as chest tube
competence, pericardial and/or pleural ﬂuid accumulation, infection,
and adverse events. Adverse events between discharge from hospital
until most recent follow-up were also recorded. Feasibility endpoints
were deﬁned as system functionality and labor-intensiveness. Transtho-
racic echocardiograms (TTE) and chest radiographs were the imaging
modalities of choice that were used to evaluate pericardial and pleural
effusions on arrival in ICU, at 5–7 days postoperatively, and on dis-
charge. Pericardial or pleural effusions that were clinically signiﬁcant
and required drainage were registered.
Table 1
Clinical characteristics of the CPPF and non-CPPF groups.
CPPF Non-CPPF P value
n = 21 (%) n = 126 (%)
Mean age (years ± SD) 43.8 ± 13.6 40.5 ± 15.0 0.353
Male/female 11/10 73/53 0.637
Body mass index (mean ± SD (kg/m2)) 27.5 ± 7.0 24.3 ± 4.6 0.057
Diagnoses:
Tetralogy of Fallot 6 (28.6) 14 (11.1) 0.109
Transposition of the great arteries 1 (4.8) 8 (6.3) 0.781
Univentricular heart 0 (0.0) 3 (2.4) 0.478
Connective tissue disease 0 (0.0) 16 (12.7) b0.001*
Fabry syndrome 1 (4.8) 1 (0.8) 0.420
Factor V Leiden 1 (4.8) 1 (0.8) 0.420
Associated diseases:
BMI N30 kg/m2 5 (23.8) 11 (8.7) 0.142
Diabetes 1 (4.8) 4 (3.2) 0.518
Renal insufﬁciency (at least moderate) 6 (28.6) 18 (14.3) 0.189
Chronic obstructive lung disease 2 (9.5) 7 (5.6) 0.486
Urgent/emergency surgery 0 (0.0) 1 (0.8) 0.685
Left ventricular ejection fraction:
N50% 14 (66.6) 106 (84.1) 0.127
30–50% 7 (33.3) 18 (14.3) 0.096
b30% 0 (0.0) 2 (1.6) 0.564
Euroscore I (logistic) (mean ± SD) 6.14 ± 7.27 7.51 ± 6.67 0.389
Euroscore II (mean ± SD) 2.90 ± 2.97 2.84 ± 2.63 0.916
Preoperative anticoagulant use:a
Acetylsalicylic acid 6 (28.6) 23 (18.3) 0.274
Vitamin K antagonists 4 (19.0) 10 (7.9) 0.235
Other 0 (0.0) 1 (0.8) 0.685
Preoperative laboratory values:
Hemoglobin (mmol/l) 8.8 ± 0.7 8.9 ± 0.9 0.831
CRP (mg/l) 4.0 ± 4.4 3.6 ± 6.4 0.903
Leukocytes (×109/l) 7.5 ± 2.1 6.4 ± 1.7 0.009*
Platelet count (×109/l) 221 ± 70 219 ± 55 0.869
INR (median; Q1; Q3; IQR) 1.08 (0.98;
1.62; 0.64)
0.99 (0.96;
1.08; 0.12)
0.160
a Use of all antiplatelet agents was discontinued 5 days prior to surgery. CRP =
C-reactive protein; INR = international normalized ratio.
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Secondary endpoints included transfusion requirements, time to
chest tube removal, time to extubation and length of ICU and hospital
stay. Transfusion requirements were deﬁned as total PRBC, total FFP,
and total platelet concentrate transfusions as well as the proportion
of patients requiring blood product transfusion. The time frames
between operation and chest tube removal and between operation
and extubation were recorded in postoperative hours.
2.7. Statistical Analysis
Variables are presented as mean (±standard deviation) or as num-
ber (percentage), unless otherwise noted. An independent-samples t-
test was conducted to compare mean actual blood loss between the
CPPF and non-CPPF group; a P value b 0.05 was considered statistically
signiﬁcant. All data analyses were performed using SPSS 20.0 for
Macintosh (IBM® SPSS® Software). Mean actual blood loss curves
were plotted using GraphPad Prism® 6.0 software for Macintosh.
2.8. Funding
This study was funded intramural with resources from the
department of cardiothoracic surgery of the Academic Medical Center,
Amsterdam, The Netherlands.
3. Results
3.1. Demographic and Preoperative Clinical Data
Preoperatively we registered there were two signiﬁcant differences
between the CPPF and the non-CPPF group of patients with respect to
demographic and clinical characteristics as shown in Table 1.
3.2. Surgical Procedures and Operative Data
On comparison with the CPPF group patients in the non-CPPF
group had undergone signiﬁcantly more procedures for left-sided
lesions (P = 0.030), aortic root surgery (P = b0.001), aortic valve
replacement (P = 0.008), and Bentall procedure (P = 0.008). Patients
in the CPPF group underwent signiﬁcantly more procedures for right-
sided lesions (P = b0.001). The complexity of surgical procedures is
shown in Table 2. Intraoperative variables such as the duration of CPB
and aortic cross-clamping were similar in both groups and are present-
ed in Table 3.
3.3. CPPF Safety and Feasibility
Postoperative safety aspects of the CPPF group and historic group of
patients are summarized in Table 4. CPPF was successfully completed in
20 (95.2%) patients. In 1 (4.8%) patient, CPPF was stopped as a precau-
tion 3.5 h postoperatively as there was a N200 ml lag in MCTD volume
as ﬂuid had accumulated in the right pleural cavity. On extubation the
patient spontaneously evacuated all accumulated ﬂuid, which was con-
ﬁrmed by chest radiography. All irrigation solution was successfully
evacuated from the pericardial and/or pleural cavities in all patients
before the chest tubes were removed. There were no signiﬁcant
differences between groups in pleural effusions (P= 0.272) or pericar-
dial effusions (P = 0.486) at discharge. Postoperative inﬂammatory
markers were not signiﬁcantly different between groups.
No system-related or other serious problems were encountered.
Monitoring of inﬂow and outﬂow volumes was considered time-
consuming but feasible in this experimental settingwhere themonitor-
ing was safeguarded and controlled by a research assistant. However, it
was considered to be a major drawback for normal clinical setting as it
would be a signiﬁcant increase in workload for the ICU nurse andrepeated calculation will be error prone. Especially in case of bleeding
problems when a more frequent monitoring and calculation of actual
blood loss is required. Also, the normal clinical assessment of blood
content of MCTD is disturbed as the blood is constantly diluted in
varying degrees.3.4. Effect on Mean Actual Blood Loss
Differences inmean actual blood loss on arrival at ICU, at 6 and 12-h
postoperatively, and the total postoperative blood loss between
the CPPF group and non-CPPF group are presented in Table 5. The
magnitudes of the signiﬁcant decrease in means were 41% (mean
difference = 57 ml, 95% CI: 12 to 102) on arrival at ICU and 30%
(mean difference = 162 ml, 95% CI: 9 to 315) at 12 h postoperatively;
both had a moderate effect (eta squared = 0.04 and 0.03 respectively).
Within the non-CPPF group, those who underwent aortic root surgery
had 65ml (P= 0.286) less blood loss at 12 h postoperatively compared
to the non-aortic root surgery group. Postoperative mean actual
blood loss over hourly intervals and the cumulative total over the ﬁrst
12 postoperative hours is shown in Fig. 1.3.5. Secondary Endpoints
Differences in allogeneic transfusion requirements between the two
groups were not statistically signiﬁcant as shown in Table 5. No signiﬁ-
cant differences in means between the two groups were foundwith re-
spect to the time to extubation (P= 0.535), time to chest tube removal
(P = 0.762), length of ICU stay (P = 0.746), and total hospitalization
(P = 0.472).
Table 2
Surgical procedures of the CPPF and non-CPPF groups.
CPPF Non-CPPF P value
n = 21 (%) n = 126 (%)
Aortic surgery:
AVP 0 (0.0) 1 (0.8) 0.685
AVR+Asc. Repl. (0|2); +PVR (0|1); +MVP, PVI (0|1); +VSD repair (0|1) 0 (0.0) 7 (5.6) 0.008*
Bentall+PVR (1|4); +Hemiarch Repl. (0|1); +MVP, TVP (0|3); +VSD repair (0|2) 1 (4.8) 27 (21.4) 0.008*
VSRR+AVP (0|3); +MVP (0|2) 1 (4.8) 20 (15.9) 0.061
Ascending aorta replacement+MVP (0|1) 0 (0.0) 4 (3.2) 0.411
Hemiarch replacement + ductus closure 0 (0.0) 1 (0.8) 0.685
Atrioventricular valve surgery:
MVP+PVI (1|3); +TVP (0|6); +VSD repair (0|2) 1 (4.8) 12 (9.5) 0.480
MVR 0 (0.0) 5 (4.0) 0.356
TVP 0 (0.0) 4 (3.2) 0.411
Septal defects:
ASD I, MVP, TVP 2 (9.5) 1 (0.8) 0.201
ASD II+MVP, TVP (2|1); +TVP (1|3); +PVP (0|1) 2 (9.5) 6 (4.8) 0.377
VSD+TVP (1|1); +DCRV (1|0) 2 (9.5) 3 (2.4) 0.298
Pulmonary venous anomalies:
PAPVC repair+ASD (1|4); +TVP (1|1) 2 (9.5) 5 (4.0) 0.422
Coronary artery anomalies:
ALCAPA/ARCAPA repair+PA plasty (0|2); +CABG (0|1) 2 (9.5) 3 (2.4) 0.298
Other:
PVR+PA plasty (5|16); +TVP (1|4); +MVP (1|0) 7 (33.3) 20 (15.9) 0.127
AP plasty + hybrid stent placement 0 (0.0) 1 (0.8) 0.685
DSAS repair/morrow 0 (0.0) 1 (0.8) 0.685
Atrial bafﬂe + TVP 1 (4.8) 2 (1.6) 0.344
TCPC 0 (0.0) 3 (2.4) 0.478
ALCAPA=anomalous left coronary artery from the pulmonary artery; ARCAPA=anomalous right coronary artery from the pulmonary artery; Asc.= ascending aorta; ASD=atrial septal
defect; AVP = aortic valve plasty; DCRV = double-chambered right ventricle; DSAS = discrete subaortic stenosis; MVP = mitral valve plasty; MVR =mitral valve replacement; PA =
pulmonary artery; PAPVC = partial anomalous pulmonary venous connection; PVI = pulmonary vein isolation; PVP = pulmonary valve plasty; PVR = pulmonary valve replacement;
Repl. = replacement; TCPC = total cavopulmonary connection; TVP = tricuspid valve plasty; VSD = ventricular septal defect.
Table 4
Postoperative safety aspects of the CPPF and non-CPPF groups.
CPPF Non-CPPF P value
n = 21 (%) n = 126 (%)
In-hospital adverse events:
Cardiac tamponade 0 (0.0) 4 (3.2) 0.411
Reexploration for bleeding 0 (0.0) 9 (7.1) 0.002*
Subxyphoidal drainage 0 (0.0) 3 (2.4) 0.478
Mortality 0 (0.0) 2 (1.6) 0.564
In-hospital infection:
Sternal wound infection 0 (0.0) 3 (2.4) 0.478
Mediastinitis 0 (0.0) 2 (1.6) 0.564
Pneumonia 1 (4.8) 3 (2.4) 0.538
Urine tract infection 1 (4.8) 1 (0.8) 0.420
Fever N38.5 °C 2 (9.5) 9 (7.1) 0.703
Max. CRP
(mg/l, median; Q1; Q3; IQR)
138
(95;200;105)
182
(136;231;95)
0.057
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There are several techniques available that aim to reduce blood loss
and associated exposure to allogeneic blood after surgery. These include
minimally invasive surgical techniques, blood conservation strategies
(Hardy et al., 1996), extracorporeal circulation systems (Abdel Aal
et al., 2011) and, the systemic (Henry et al., 2011; Levi et al., 1999)
and topical (Ker et al., 2013) pharmacological correction of hemostasis.
Despite the improvements achieved by these techniqueswe still tend to
accept a considerable amount of blood loss as being inherent to cardiac
surgery.Moreover, all techniques available have different targets and/or
time of action than the CPPF. Therefore, regardless of their effects, the
result of CPPF is always an additional improvement to the current
state of the art.
Reviewof literature revealed only a few studies thatwere focused on
chest tube functionality and improvement of thepostoperative drainageTable 3
Operative data of the CPPF and non-CPPF groups.
CPPF Non-CPPF P value
n = 21 (%) n = 126 (%)
Reoperation 10 (47.6) 57 (45.2) 0.841
Left sided lesions 9 (42.9) 85 (67.5) 0.030*
Right sided lesions 17 (81.0) 56 (44.4) b0.001*
Aortic root surgery 2 (9.5) 65 (51.6) b0.001*
Septal defects 6 (28.6) 21 (16.7) 0.274
Pulmonary venous anomalies 2 (9.5) 5 (4.0) 0.422
Coronary artery anomalies 2 (9.5) 3 (2.4) 0.298
Single procedure 8 (38.1) 63 (50.0) 0.320
Double procedure 11 (52.4) 43 (34.1) 0.110
Triple procedure 1 (4.8) 18 (14.3) 0.103
Quadruple procedure 1 (4.8) 2 (1.6) 0.344
Mean surgical procedures per patient 1.76 1.67 0.230
Mean CPB time (min) ± SD 140 ± 72 151 ± 63 0.443
Mean cross-clamp time (min) ± SD 86 ± 41 101 ± 46 0.186
Max. Leukocytes
(×109/l, median; Q1; Q3; IQR)
13.5
(11.1;15.9;4.8)
12.6
(10.7;15.8;5.1)
0.867
In-hospital data:a
Time until extubation (hours ± SD) 7.6 ± 6.1 6.8 ± 5.2 0.535
Timeuntil chest tube removal (hours±SD) 21 ± 8 22 ± 14 0.762
ICU stay (days ± SD) 1.4 ± 0.9 1.7 ± 3.8 0.746
Total hospitalization (days ± SD) 7.7 ± 2.4 9.0 ± 8.6 0.472
Fluid accumulation at discharge:
Pleural effusion (trace to mild) 10 (47.6) 77 (61.1) 0.272
In a surgically opened pleural cavity 5 (23.8) 23 (18.3) 0.563
Pericardial effusion (trace to mild) 7 (33.3) 38 (30.2) 0.486
Circular (≥50%/≥6 mm) 1 (4.8) 10 (7.9) 0.606
Adverse events after discharge:
Late cardiac tamponade 1 (4.8) 3 (2.4) 0.477
For which subxyphoidal drainage 1 (4.8) 2 (1.6) 0.344
For which re-sternotomy 0 (0.0) 1 (0.8) 0.685
Reoperation 1 (4.8) 4 (3.2) 0.718
3-year mortality 0 (0.0) 6 (4.8) 0.014*
Mean follow-up (years ± SD) 2.9 ± 0.1 4.1 ± 1.0 b0.001*
a Time until extubation and chest tube removal were deﬁned as the mean number of
hours between surgery and the time of removal. Length of ICU and hospital stay were
deﬁned as the mean number of days between the date of surgery and the date of ICU
and hospital discharge, respectively.
Table 5
Blood loss and PRBC transfusion requirements of the CPPF and non-CPPF groups.
CPPF Non-CPPF P value
n = 21 (%) n = 126 (%)
Postoperative blood loss: (mean ± SD)
T0: ICU arrival 83 ± 74 140 ± 100 0.014*
T6: 6 h postoperative 310 ± 195 415 ± 297 0.131
T12: 12 h postoperative 376 ± 249 538 ± 330 0.038*
Total postoperative 608 ± 422 768 ± 630 0.263
PRBC transfusion requirements:
Patients transfused PRBC intraoperatively 7 (33.3) 38 (30.2) 0.772
Patients transfused PRBC postoperatively 1 (4.8) 19 (15.0) 0.080
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None of the studies reported a technique similar to CPPF as described in
our paper. In addition, none of the postoperative drainage systems
initially aimed for the complete cleaning of the pericardial space of
blood and clots and, also, did not have reduction of blood loss as a
primary study end point. Thus, to our knowledge, a ﬂushing system
that has speciﬁcally been designed to promote the evacuation of con-
taminated blood and clots out of the pericardial cavity in order to reduce
postoperative blood loss has not been used or described before.Fig. 1. Postoperative actual blood loss over hourly intervals (A) andCPPF showed a 30% reduction in 12-hour postoperative blood loss
and there were no re-explorations for bleeding complications in the
CPPF group. The non-CPPF group included signiﬁcantly more aortic
root surgery but within the non-CPPF group, procedures on the aortic
root showed even less blood loss when compared to those that had
non-aortic root surgery.With respect to important bleeding parameters
(percentage of redo surgery, cross-clamp and CPB time, single andmul-
tiple procedures, use of anticoagulants, EUROSCORES) no signiﬁcant dif-
ferences were found between the groups. None of the other signiﬁcant
differences between the two groups, as depicted in Tables 1–3, are
known to have implications with respect to more or less bleeding ten-
dency. Overall, the mean postoperative blood loss in both the CPPF
and non-CPPF group can be considered to be low given the surgical
complexity and high percentage of reoperations; this makes the
difference that we found stronger. However, the evidence from this
pilot study (prospective cohort in comparison with a historic group of
patients) is not strong enough to draw deﬁnitive conclusions with
respect to blood loss and bleeding complications. Currently, two
randomized clinical trials are ongoing at our institution that need to
provide proof of concept by conﬁrmation of these pilot ﬁndings.
On the contrary, one can also put forward that ﬂushing a fresh
wound carries the risk of disturbing the normal coagulation process,
which therefore may lead to increased blood loss. Considering the littletotal cumulatively (B) during the ﬁrst 12 postoperative hours.
1222 J.S.J. Manshanden et al. / EBioMedicine 2 (2015) 1217–1223amount of blood loss thatwe observed in theCPPF group (mean376ml)
and the fact that no continued bleeding was observed, we may abstract
that CPPF patients did not tend to havemore blood losswhen compared
to the “normal” non-CPPF patients. It is likely that this phenomenon did
not occur is because our ﬂushing method includes a slow continuous
irrigation of ﬂushing ﬂuid rather than hosing the wound using strong
mechanical forces. CPPF works mainly by dilution and lowering the
viscosity of the blood and clot mixture in the wound, which enhances
evacuation through the chest tubes.
Surgical re-exploration bleeding or suspected or acute cardiac
tamponade is associated with increased mortality and morbidity
(Haneya et al., 2015) and is still needed in 2–6% of patients (Karthik
et al., 2004; Biancari et al., 2012). As well as its effect on blood loss,
CPPF may have an important impact on the prevention of acute cardiac
tamponade, which was not seen in the CPPF group. As stated above,
CPPF lowers the viscosity of drainage ﬂuid and prevents abundant
formation of clots, thereby preventing the chest tubes from blocking
and promoting chest tube patency. Even the use of multiple rather
than single mediastinal chest tubes is known not to solve this problem
(Le et al., 2015).
In theory, partial or complete chest tube blockage can never be
completely eliminated, which emphasizes the need for careful monitor-
ing of inﬂowand outﬂowvolumes. Intrapericardial pressuremonitoring
could serve as an extra safety assurance. CPPF requires real-time accu-
rate quantiﬁcation of MCTD volume within the CPPF window in order
to monitor actual blood loss and to trace possible ﬂuid accumulation
in the pericardial and/or pleural cavity. The manual monitoring proce-
dure at time intervals that was used in this study was considered
labor intensive and should ideally be automated for future clinical use.
For the clinical assessment of actual blood loss and the detection of
surgical hemorrhage, the blood content of MCTD must be known at
any time. Therefore, real time monitoring of hematocrit values of
MCTD seems indispensable.
On TTE on discharge no signiﬁcant differences in pericardial effusion
were found between the CPPF group and non-CPPF group of patients,
and no clinically signiﬁcant pericardial effusions were encountered in
the CPPF group. CPPF was stopped in one patient 3.5 h postoperatively
as a precautionary measure due to a lag of N200 ml of ﬂuid drainage
from the right pleural cavity. As long as the protocol is followed strictly,
i.e., the maximum accumulation volume does not exceed 200 ml,
these pericardial or pleural effusions may be considered as clinically
insigniﬁcant.
CPPF requires insertion of an extra drain and infusion of a saline so-
lution into a fresh wound area, thereby theoretically increasing the risk
of infection. However, since both the infusion solution and drain are
sterilized and the same incision is used as for the standard chest tubes,
this risk is considered to be negligible. No manifest clinical infections
were seen in the CPPF group. Continuous irrigation of the wound area
may reduce bacterial load and in theory decrease the risk of infection.
In addition, by evacuating all blood and clots an important nutrient
medium for potential bacterial infections is eliminated. Besides this,
blood outside the vascular system i.e., in the pericardial cavity, may it-
self induce a serious local inﬂammatory reaction. Aiming for a cleaner
pericardial space, CPPFmay reduce postoperative complications related
to this inﬂammatory process. In this context, the effect of CPPF on atrial
ﬁbrillation (Bruins et al., 1997), the development of adhesions (Nkere et
al., 1995; Cannata et al., 2013) and impaired postoperative right
ventricular function (Bailey et al., 1984; Schuuring et al., 2012) will be
the subject of future studies.
In summary, so far CPPF can be regarded as safe since no postopera-
tive adverse events that could be related to the CPPF were encountered
in this study. In this experimental setting the CPPF method was consid-
ered feasible. However, in our judgment the CPPFmethodmust be auto-
mated and the system should be equipped with an intra-pericardial
pressure sensor and real-time hematocrit analysis of MCTD to provide
the required high level of safety and feasibility in the clinical setting.A limitation of this study is the retrospective group comparison.
Results regarding the clinical impact on blood loss reduction are not
yet conclusive at this stage and therefore randomized clinical trials are
mandatory for a ﬁnal conclusion. For instance, the surgical procedures
in the CPPF group may have been biased towards “dryer surgery”.
Also, the difference between inﬂow and outﬂow volumes may not be
an accurate measure for actual blood loss while the composition of
MCTD ﬂuid is both variable in time and patient-dependent.
5. Conclusion
From our study ﬁndings we conclude that CPPF after cardiac surgery
is safe and feasible in this experimental setting. A positive effect
on blood loss and related complications may be anticipated, but
standardized randomized clinical trials are necessary to draw deﬁnitive
conclusions.
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